Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor

Muhammad Rafehi, Enas M. Malik, Alexander Neumann, Aliaa Abdelrahman, Theodor Hanck, Vigneshwaran Namasivayam, Christa E. Müller, Younis Baqi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

P2Y4 is a Gq protein-coupled receptor activated by uridine-5′-triphosphate (UTP), which is widely expressed in the body, e.g., in intestine, heart, and brain. No selective P2Y4 receptor antagonist has been described so far. Therefore, we developed and optimized P2Y4 receptor antagonists based on an anthraquinone scaffold. Potency was assessed by a fluorescence-based assay measuring inhibition of UTP-induced intracellular calcium release in 1321N1 astrocytoma cells stably transfected with the human P2Y4 receptor. The most potent compound of the present series, sodium 1-amino-4-[4-(2,4-dimethylphenylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-16133, 61) exhibited an IC50 value of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand-receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known to date. Compounds 61 and 64 are therefore anticipated to become useful tools for studying this scarcely investigated receptor.

Original languageEnglish
Pages (from-to)3020-3038
Number of pages19
JournalJournal of Medicinal Chemistry
Volume60
Issue number7
DOIs
Publication statusPublished - Apr 13 2017

Fingerprint

Uridine Triphosphate
Gq-G11 GTP-Binding Protein alpha Subunits
Sodium
Anthraquinones
Astrocytoma
Inhibitory Concentration 50
Intestines
Fluorescence
Ligands
Calcium
purinoceptor P2Y4
Brain

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor. / Rafehi, Muhammad; Malik, Enas M.; Neumann, Alexander; Abdelrahman, Aliaa; Hanck, Theodor; Namasivayam, Vigneshwaran; Müller, Christa E.; Baqi, Younis.

In: Journal of Medicinal Chemistry, Vol. 60, No. 7, 13.04.2017, p. 3020-3038.

Research output: Contribution to journalArticle

Rafehi, M, Malik, EM, Neumann, A, Abdelrahman, A, Hanck, T, Namasivayam, V, Müller, CE & Baqi, Y 2017, 'Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor', Journal of Medicinal Chemistry, vol. 60, no. 7, pp. 3020-3038. https://doi.org/10.1021/acs.jmedchem.7b00030
Rafehi M, Malik EM, Neumann A, Abdelrahman A, Hanck T, Namasivayam V et al. Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor. Journal of Medicinal Chemistry. 2017 Apr 13;60(7):3020-3038. https://doi.org/10.1021/acs.jmedchem.7b00030
Rafehi, Muhammad ; Malik, Enas M. ; Neumann, Alexander ; Abdelrahman, Aliaa ; Hanck, Theodor ; Namasivayam, Vigneshwaran ; Müller, Christa E. ; Baqi, Younis. / Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 7. pp. 3020-3038.
@article{8ba870fab55e417b8ccc18ce028056de,
title = "Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor",
abstract = "P2Y4 is a Gq protein-coupled receptor activated by uridine-5′-triphosphate (UTP), which is widely expressed in the body, e.g., in intestine, heart, and brain. No selective P2Y4 receptor antagonist has been described so far. Therefore, we developed and optimized P2Y4 receptor antagonists based on an anthraquinone scaffold. Potency was assessed by a fluorescence-based assay measuring inhibition of UTP-induced intracellular calcium release in 1321N1 astrocytoma cells stably transfected with the human P2Y4 receptor. The most potent compound of the present series, sodium 1-amino-4-[4-(2,4-dimethylphenylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-16133, 61) exhibited an IC50 value of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand-receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known to date. Compounds 61 and 64 are therefore anticipated to become useful tools for studying this scarcely investigated receptor.",
author = "Muhammad Rafehi and Malik, {Enas M.} and Alexander Neumann and Aliaa Abdelrahman and Theodor Hanck and Vigneshwaran Namasivayam and M{\"u}ller, {Christa E.} and Younis Baqi",
year = "2017",
month = "4",
day = "13",
doi = "10.1021/acs.jmedchem.7b00030",
language = "English",
volume = "60",
pages = "3020--3038",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor

AU - Rafehi, Muhammad

AU - Malik, Enas M.

AU - Neumann, Alexander

AU - Abdelrahman, Aliaa

AU - Hanck, Theodor

AU - Namasivayam, Vigneshwaran

AU - Müller, Christa E.

AU - Baqi, Younis

PY - 2017/4/13

Y1 - 2017/4/13

N2 - P2Y4 is a Gq protein-coupled receptor activated by uridine-5′-triphosphate (UTP), which is widely expressed in the body, e.g., in intestine, heart, and brain. No selective P2Y4 receptor antagonist has been described so far. Therefore, we developed and optimized P2Y4 receptor antagonists based on an anthraquinone scaffold. Potency was assessed by a fluorescence-based assay measuring inhibition of UTP-induced intracellular calcium release in 1321N1 astrocytoma cells stably transfected with the human P2Y4 receptor. The most potent compound of the present series, sodium 1-amino-4-[4-(2,4-dimethylphenylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-16133, 61) exhibited an IC50 value of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand-receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known to date. Compounds 61 and 64 are therefore anticipated to become useful tools for studying this scarcely investigated receptor.

AB - P2Y4 is a Gq protein-coupled receptor activated by uridine-5′-triphosphate (UTP), which is widely expressed in the body, e.g., in intestine, heart, and brain. No selective P2Y4 receptor antagonist has been described so far. Therefore, we developed and optimized P2Y4 receptor antagonists based on an anthraquinone scaffold. Potency was assessed by a fluorescence-based assay measuring inhibition of UTP-induced intracellular calcium release in 1321N1 astrocytoma cells stably transfected with the human P2Y4 receptor. The most potent compound of the present series, sodium 1-amino-4-[4-(2,4-dimethylphenylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-16133, 61) exhibited an IC50 value of 233 nM, selectivity versus other P2Y receptor subtypes, and is thought to act as an allosteric antagonist. A receptor homology model was built and docking studies were performed to analyze ligand-receptor interactions. Compound 64 (PSB-1699, sodium 1-amino-4-[4-(3-pyridin-3-ylmethylthio)phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate) represents the most selective P2Y4 receptor antagonist known to date. Compounds 61 and 64 are therefore anticipated to become useful tools for studying this scarcely investigated receptor.

UR - http://www.scopus.com/inward/record.url?scp=85017548237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017548237&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b00030

DO - 10.1021/acs.jmedchem.7b00030

M3 - Article

VL - 60

SP - 3020

EP - 3038

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -